Market Performance - The pharmaceutical commercial sector increased by 0.17% compared to the previous trading day, with XD Yifeng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with XD Yifeng Pharmaceutical closing at 26.22, up 2.66%, and Dazhenglin at 17.66, up 2.56% [1] - Other notable performers included Liuyao Group at 18.90, up 1.02%, and China Pharmaceutical at 10.95, up 0.83% [1] Trading Volume and Value - XD Yifeng Pharmaceutical had a trading volume of 106,700 shares and a transaction value of 279 million yuan [1] - Dazhenglin recorded a trading volume of 72,200 shares with a transaction value of 126 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 225 million yuan from institutional investors, while retail investors saw a net inflow of 205 million yuan [2] - Speculative funds had a net inflow of approximately 19.83 million yuan [2] Individual Stock Capital Flow - China Pharmaceutical had a net inflow of 20.91 million yuan from institutional investors, while it faced a net outflow of 8.68 million yuan from retail investors [3] - Liuyao Group saw a net inflow of 7.14 million yuan from institutional investors, but a net outflow of 10.03 million yuan from retail investors [3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 6.30 CNY based on a 14x PE ratio for 2025 [3][6]. Core Views - The company has shown steady revenue growth, with a 5.1% year-on-year increase in H1 2025, achieving a revenue of 811.1 billion CNY and a net profit of 14.5 billion CNY, which is a 19.7% increase year-on-year [10]. - The company is actively pursuing strategic transformation, focusing on enhancing its operational efficiency and expanding its market presence in new retail and e-commerce channels [10]. - The financial forecasts for 2025-2027 have been adjusted, with expected earnings per share of 0.45, 0.47, and 0.53 CNY respectively, reflecting a downward revision from previous estimates [3][5]. Financial Summary - The company's revenue is projected to grow from 150.14 billion CNY in 2023 to 186.71 billion CNY in 2027, with a compound annual growth rate (CAGR) of approximately 7.1% [5][12]. - Operating profit is expected to decline in 2025 to 3.36 billion CNY, down from 3.64 billion CNY in 2024, before recovering to 3.97 billion CNY in 2027 [5][12]. - The net profit attributable to the parent company is forecasted to decrease to 2.27 billion CNY in 2025, with a subsequent increase to 2.68 billion CNY by 2027 [5][12]. - The gross margin is expected to stabilize around 7.8% from 2025 to 2027, while the net margin remains consistent at 1.4% [5][12].

Core Insights - Royal jelly is a rare natural complex nutrient with significant value in enhancing immunity, anti-aging, endocrine regulation, and improving sleep [1][6] - China is the world's largest producer and exporter of royal jelly, with an annual production of nearly 1,000 tons, over 90% of which is for export [1][6] - In 2024, China's royal jelly exports reached 623.81 tons, an increase of 11.12 tons from 2023, with export value at 14.53 million USD, up by 1.89 million USD [1][6] - However, in the first seven months of 2025, exports declined by 16.5% in quantity and 20.2% in value due to natural factors affecting production and rising market prices [1][6] Industry Overview - Royal jelly, also known as bee milk, is secreted by young worker bees and is rich in active ingredients with various health benefits [3][4] - The industry has evolved through four stages: initial awareness, primary development, significant production increase, and modernized development with advanced technology [4][5] Industry Chain - The royal jelly industry chain includes upstream beekeeping and processing equipment, midstream manufacturers, and downstream sales channels such as health product companies and e-commerce platforms [5][6] Current Market Status - The market for royal jelly is competitive with numerous brands, where well-known brands dominate due to product quality and market share [6][10] - Key companies in the industry include Nanjing Laoshanyao Pharmaceutical Co., Ltd., Jiangxi Wang's Beekeeping Garden Co., Ltd., and Hangzhou Bee's Language Co., Ltd. [6][9] Export Data - Major export regions for Chinese royal jelly include Spain and Japan, accounting for over 50% of total exports [6][10] - In the first half of 2025, Zhejiang province led in exports, followed by Jiangsu and Shanghai, with varying growth rates across provinces [8][10] Future Trends - Market demand for royal jelly is expected to grow due to increasing consumer awareness of natural health products [10][11] - The industry is moving towards intelligent, automated, and sustainable production methods, enhancing efficiency and quality [11][12] - There is a trend towards functional and diversified products, with advancements in biotechnology enabling the development of customized health products [12]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 6.30 CNY based on a 14x PE ratio for 2025 [3][6]. Core Views - The company has shown steady revenue growth, with a projected increase in revenue from 150.14 billion CNY in 2023 to 186.71 billion CNY by 2027, reflecting a CAGR of approximately 7.1% [5][10]. - The net profit attributable to the parent company is expected to decline slightly in 2025 to 2.27 billion CNY, before recovering to 2.68 billion CNY in 2027, indicating a focus on strategic transformation and operational efficiency [5][10]. - The company is actively pursuing a strategic transformation, focusing on new retail operations and enhancing its product offerings, including a significant increase in medical beauty revenue by 48.6% in the first half of 2025 [10]. Financial Summary - Revenue projections for 2025-2027 are adjusted to 162.73 billion CNY, 174.35 billion CNY, and 186.71 billion CNY respectively, with corresponding net profits of 2.27 billion CNY, 2.38 billion CNY, and 2.69 billion CNY [5][10]. - The gross margin is expected to stabilize around 7.8% from 2025 onwards, while the net margin remains consistent at 1.4% [5][10]. - The company’s operating profit is forecasted to decrease by 7.5% in 2025, followed by a recovery in subsequent years, indicating a focus on cost management and efficiency improvements [5][10].

Group 1 - The issuer of the convertible bonds is Yifeng Pharmacy Chain Co., Ltd. [2] - The total amount of the convertible bonds issued is RMB 179,743.20 million, with a net fundraising amount of RMB 178,026.23 million after deducting issuance fees [3][4] - The bonds will be listed on the Shanghai Stock Exchange starting from March 27, 2024, under the name "Yifeng Convertible Bonds" with the code "113682" [3][4] Group 2 - The bonds have a maturity period of six years, from March 4, 2024, to March 3, 2030 [4] - The face value of each bond is RMB 100, and the bonds are issued at face value [5] - The coupon rates for the bonds are set at 0.30% for the first year, increasing to 2.00% by the sixth year [6] Group 3 - The initial conversion price for the bonds is set at RMB 39.85 per share [13] - The conversion price will be adjusted based on various corporate actions, including stock dividends and cash distributions [34] - The conversion price has been adjusted multiple times, with the latest adjustment bringing it down to RMB 31.84 per share effective from September 17, 2025 [16][17][34] Group 4 - The company has established a management system for the raised funds, which will be deposited in a designated special account [30] - The bonds have been rated AA by a credit rating agency, with a stable outlook [30] - The company is required to redeem the bonds at 110% of the face value upon maturity, including the last interest payment [23]

债券简称：益丰转债 债券代码：113682 中信证券股份有限公司关于 益丰大药房连锁股份有限公司 向不特定对象发行可转换公司债券 2025年第二次临时受托管理事务报告 发行人 益丰大药房连锁股份有限公司 Yifeng Pharmacy Chain Co., Ltd. （湖南省常德市武陵区白马湖街道富强社区人民路 2638 号） 债券受托管理人 中信证券股份有限公司 （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 2025 年 9 月 1 重要声明 本报告依据《可转换公司债券管理办法》《公司债券发行与交易管理办法》 （以下简称《管理办法》）、《公司债券受托管理人执业行为准则》（以下简称 《执业行为准则》）等相关规定及其它相关信息披露文件、益丰大药房连锁股份 有限公司（以下简称"益丰药房"，"发行人"或"公司"）出具的相关文件以 及提供的相关资料或第三方中介机构出具的专业意见等，由本期公司债券受托管 理人中信证券股份有限公司（以下简称"中信证券"）编制。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中信证券所作的承诺 或声 ...

Core Insights - The Shandong Provincial Market Supervision Administration conducted a quality inspection of 54 batches of elderly walking shoes, revealing that 11 batches from various sellers did not meet the required standards [3][4]. Group 1: Inspection Results - A total of 54 batches of elderly walking shoes were inspected, with 38 batches from retail and 16 batches from online sales [3]. - The inspection focused on various quality parameters, including peel strength, durability, abrasion resistance, and color fastness [3]. - 11 batches from sellers such as Cai Guoxiang and Feicheng Xinyi Business Co., Ltd. failed to meet standards, particularly in durability and abrasion resistance [3][4]. Group 2: Regulatory Actions - The Shandong Provincial Market Supervision Administration has mandated relevant departments to handle the non-compliance results according to the Product Quality Law and related regulations [4].

Summary of Conference Call on Pharmacy Industry Industry Overview - The pharmacy industry is undergoing a transformation towards differentiation due to long-term profit erosion from drug sales. Future directions include professional monetization (embracing medical insurance and commercial insurance) and diversified transformation, characterized by the "thousand stores, thousand faces" approach and digital product selection [1][2]. Key Points and Arguments - **Challenges Facing the Pharmacy Industry**: The industry is experiencing slow growth due to economic changes, policy adjustments, and shifts in consumer habits post-pandemic. The trend of medical insurance cost control is impacting profitability [2][5]. - **Head Pharmacy Initiatives**: Leading pharmacies like YaoXingTang and YiFeng have cleared unprofitable stores and are piloting store upgrades. These upgrades are expected to significantly impact performance and valuation in 2025 and 2026 [3][4]. - **Market Valuation**: Current pharmacy valuations are at historical lows, indicating potential for upward movement as the industry undergoes transformation [4]. - **Membership System Issues**: The aging membership system is a concern, with 2024 data showing that average member consumption in the pharmacy industry is 69%. There is a need for younger consumer engagement [5]. - **Japanese Experience**: Japan's separation of medicine and pharmacy has led to significant increases in prescription outflow, providing a model for China to enhance its pharmacy ecosystem [6][7]. Additional Important Insights - **Diverse Product Strategies**: Pharmacies are diversifying their product offerings beyond medical insurance products to include items like beauty products and medical devices, which can enhance revenue and attract new customers [3][11]. - **Store Layout Strategies**: Pharmacies are adjusting their layouts based on customer demographics, such as introducing blind box products in areas with a high concentration of students [12]. - **Digital Transformation**: Leading pharmacies are advancing digital initiatives to monitor sales data, which will enhance operational efficiency and profitability [14]. - **Investment Opportunities**: Investors are encouraged to focus on companies like YaoXingTang and YiFeng, which are actively pursuing store renovations and innovative strategies to improve performance and valuation [15]. Conclusion The pharmacy industry is at a pivotal point, with significant challenges and opportunities for transformation. The focus on differentiation, digitalization, and adapting to consumer needs will be crucial for future growth and profitability.

Core Viewpoint - Yifeng Pharmacy Chain Co., Ltd. will participate in the online collective reception day for investors organized by Hunan Securities Regulatory Bureau, Hunan Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. on September 19, 2025, to enhance interaction with investors [1][2]. Group 1 - The event will be held online, allowing investors to participate through the "Panorama Roadshow" website, WeChat public account, or the Panorama Roadshow APP [1]. - Company executives will communicate with investors regarding the company's 2024 annual and 2025 semi-annual performance, corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2]. - The event is scheduled for September 19, 2025, from 14:00 to 17:00 [1].

Group 1 - A total of 56 stocks received buy ratings from institutions today, with 57 buy rating records published [1] - Luzhou Laojiao received the highest attention, with two buy rating records [1] - Among the stocks rated, 11 have an upside potential exceeding 10%, with Mango Super Media having the highest potential at 40.02% [1] Group 2 - Seven stocks received their first institutional attention today, including Haoyue Nursing and Hebei Steel Resources [1] - The average increase for stocks with buy ratings today was 0.42%, outperforming the Shanghai Composite Index [1] - The pharmaceutical and biotechnology sector was the most favored, with 11 stocks listed in the buy rating list [1] Group 3 - Notable stocks with significant upside potential include Jinpai Home and Taihe New Materials, with potential increases of 27.75% and 23.89% respectively [1] - The power equipment and basic chemicals sectors also attracted institutional interest, each with five stocks listed [1]